Published on 6 May 2024 on Benzinga via Yahoo Finance
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR).
The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint.